In the news

Alio Holds Inaugural Patient & Family Advisory Council Meeting

Jun. 23, 2022 -- After formally announcing the formation of our Patient & Family Advisory Council (PFAC) last month, we convened the group to hold our first meeting on June 16, 2022. The Alio PFAC is an advisory group designed to ensure we keep the patient at the center of everything we do – from understanding unique pain points in disease management to wearability of our SmartPatch – we want to ensure our targeted solution is built with the end-user in mind. read more

PAVmed and Lucid Diagnostics Chairman & CEO Lishan Aklog, M.D. Named Top 50 Healthcare Technology CEO

May 13, 2022 -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company, and its majority-owned subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage cancer prevention medical diagnostics company, today announced that PAVmed and Lucid Chairman & Chief Executive Officer Lishan Aklog, M.D. was selected as one of the Top 50 Healthcare Technology CEOs of 2022 by The Healthcare Technology Report. read more

Neurava wins Innovation of the Year Mira Award

Apr. 23, 2022 -- Co-founders and Purdue University grad students Jay Shah and Vivek Ganesh developed a wearable device for refractory epilepsy patients who are at high risk for a deadly complication of the disease that affects one-third of people with epilepsy. The device monitors key biomarkers and sends a wireless signal to a caregiver when it detects abnormalities typically linked to the complication. read more

Alio Receives First FDA 510(k) Clearance

Apr. 13, 2022 -- Today, Alio Inc., announced it received FDA 510(k) clearance for its remote monitoring system intended for use by healthcare professionals to intermittently collect physiological data in home use settings. Collected physiological data includes skin temperature, auscultation sound data and heart rate. read more

PAVmed Announces Successful First-in-Human Implantations of its PortIO™ Intraosseous Infusion System

Mar. 17, 2022 -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, today announced that physicians at the Clinica Porto Azul in Barranquilla, Colombia successfully implanted the Company’s PortIO™ Intraosseous Infusion System in three patients—the first human implants of the device—as part of its IRB-approved first-in-human (FIH) clinical study of up to 40 patients. read more